Advertisement
ABSI vs RXRX
Which Stock Would AI Choose? Absci Corporation (ABSI) vs. Recursion Pharmaceuticals (RXRX) Stock Comparison
Key Takeaways
- Both ABSI and RXRX are clinical-stage biotechs leveraging AI for drug discovery, but ABSI specializes in antibody therapeutics while RXRX targets broader biology and chemistry applications.
- ABSI has a smaller market capitalization of approximately $604 million compared to RXRX's $1.95 billion, offering potentially higher growth volatility.
- In recent market activity, ABSI has shown stronger relative year-to-date performance, with less pronounced declines than RXRX.
- Analyst sentiment leans more positive for ABSI with a Strong Buy consensus versus Neutral for RXRX.
- Both face high cash burn typical of clinical-stage firms, but recent partnerships and milestones provide near-term catalysts.
Introduction
This comparison examines ABSI and RXRX, two innovative biotechs at the intersection of artificial intelligence and drug discovery. Both companies utilize AI platforms to accelerate therapeutic development, making them relevant for growth-oriented investors and traders interested in healthcare technology amid evolving market sentiment toward AI-driven biotech. By analyzing recent performance, business models, and market positioning, this article highlights key contrasts in momentum, risk, and potential drivers in the current environment. Traders seeking exposure to clinical-stage innovation may find value in understanding their relative strengths.
ABSI Overview and Recent Performance
Absci Corporation (ABSI) is a clinical-stage biopharmaceutical company developing AI-generated antibody therapeutics for diseases like inflammatory bowel disease and oncology. Its platform integrates generative AI with wet-lab screening to optimize candidates. In recent market activity, ABSI shares have traded around $3.95, within a 52-week range of $2.24 to $5.23, reflecting volatility common in biotech. Recent weeks saw heightened interest following Q4 earnings, which reported revenue misses but emphasized strategic advances, 2026 milestones, and AI platform updates at conferences like Needham. Cash burn concerns persist, yet analyst upgrades and preclinical progress have supported sentiment shifts, contributing to relative outperformance.
RXRX Overview and Recent Performance
Recursion Pharmaceuticals (RXRX) is a clinical-stage TechBio company decoding biology through AI, automation, and massive datasets to industrialize drug discovery across oncology, rare diseases, and more. Key programs include REC-4881 and REC-617 in mid-stage trials. Shares recently hovered near $3.69, in a 52-week band of $2.80 to $7.18, underscoring sector pressures. Over recent weeks, RXRX experienced declines despite broader market gains, influenced by post-earnings weakness (down 16.5% since last report) and leadership transitions. Positive developments include deepened Citeline partnerships for AI-powered clinical data tools, bolstering long-term platform potential amid ongoing revenue growth expectations.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the top-performing AI trading bots from its library of over 351 bots that trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for prevailing market conditions—based on metrics like annualized returns (ranging from +15.50% to +167.82%), win rates (53.91% to 87.72%), profit factors (1.50 to 11.70), and profit-to-drawdown ratios (2.07 to 22.13%)—earn a spot among the 25 featured. These bots employ diverse strategies, from short-term 5-minute scalps in semiconductors to swing trades over weeks in industrials or defense sectors, often outperforming benchmarks in volatile environments. Explore these high-conviction options to align with your trading style.
Head-to-Head Comparison
ABSI and RXRX share AI-centric business models in biotech but diverge in focus: ABSI on de novo antibody design versus RXRX’s expansive phenomics for multi-modal discovery. Growth drivers include pipelines with Phase 1/2 assets and partnerships (e.g., ABSI with AMD/Oracle; RXRX with Roche/Bayer), yet both grapple with negative EPS (earnings per share: -0.84 for ABSI, -1.44 for RXRX) and high R&D burn. Recent momentum favors ABSI with superior YTD returns and smaller-cap agility, while RXRX offers scale but greater downside exposure. Risk factors mirror biotech norms—clinical trial outcomes and funding—amplified by sector sentiment swings. Market positioning highlights ABSI’s higher analyst-implied upside potential.
Tickeron AI Verdict
Tickeron’s AI models would likely favor ABSI in the current environment due to its stronger trend consistency, relative outperformance in recent months, robust analyst support, and upcoming milestones positioning it for potential rebounds amid biotech volatility. RXRX trails on momentum but retains appeal through partnerships; probabilities tilt toward ABSI for nearer-term stability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABSI is a Buy and RXRX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABSI’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).
- ABSI’s FA Score: 0 green, 5 red.
- RXRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABSI’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).
- ABSI’s TA Score: 5 bullish, 4 bearish.
- RXRX’s TA Score: 4 bullish, 6 bearish.
Price Growth
ABSI (@Biotechnology) experienced а -5.19% price change this week, while RXRX (@Biotechnology) price change was -7.66% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.10%. For the same industry, the average monthly price growth was -7.06%, and the average quarterly price growth was -4.60%.
Reported Earning Dates
ABSI is expected to report earnings on Aug 18, 2026.
RXRX is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Biotechnology (-7.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABSI | RXRX | ABSI / RXRX | |
| Capitalization | 998M | 1.76B | 57% |
| EBITDA | -106.8M | -478.66M | 22% |
| Gain YTD | 83.381 | -18.949 | -440% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 1.84M | 65.7M | 3% |
| Total Cash | 126M | 654M | 19% |
| Total Debt | 4.42M | 72.4M | 6% |
| ABSI | RXRX | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| Momentum ODDS (%) | 4 days ago 84% | 4 days ago 83% |
| MACD ODDS (%) | 4 days ago 84% | 4 days ago 79% |
| TrendWeek ODDS (%) | 4 days ago 89% | 4 days ago 88% |
| TrendMonth ODDS (%) | 4 days ago 85% | 4 days ago 87% |
| Advances ODDS (%) | 11 days ago 89% | 8 days ago 84% |
| Declines ODDS (%) | 6 days ago 89% | 6 days ago 88% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 84% | 4 days ago 87% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DIVN | 29.03 | -0.25 | -0.85% |
| Horizon Dividend Income ETF | |||
| BMAR | 57.01 | -0.74 | -1.28% |
| Innovator U.S. Equity Buffer ETF™ - Mar | |||
| FLN | 24.40 | -0.57 | -2.29% |
| First Trust Latin America AlphaDEX® ETF | |||
| MSSM | 58.07 | -1.80 | -3.01% |
| Morgan Stanley Pathway Sm-Md Cp Eq ETF | |||
| FTC | 179.19 | -8.25 | -4.40% |
| First Trust Large Cap Gr AlphaDEX® ETF | |||